Clinical Trial Update: Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating golcadomide in combination with nivolumab for patients with Non-Hodgkin lymphoma that is refractory after CAR-T therapy ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Golcadomide (golcadomide)
• nivolumab (nivolumab)

Snippet

Sponsor: University of Pittsburgh | Conditions: Non Hodgkin Lymphoma | Phase 1, Phase 2 | Status: WITHDRAWN